# The COMBAT HBV Feasibility Trial

> **NCT05705427** · PHASE4 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 317 (actual)

## Conditions studied

- Hepatitis B
- Vertical Transmission of Infectious Disease

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate 300 MG
- **BIOLOGICAL:** Hepatitis B monovalent vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05705427
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-17
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705427, "The COMBAT HBV Feasibility Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05705427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*